MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 3 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar dutchburger (< 20) Submitted: 4/22/2010 3:22:55 AM : Outperform Start Price: $6.10 MNKD Score: -71.78

FDA approval of Mankind's new insulin dosing technology will be paradigm shift for diabetes patients. The Dreamboat dosing system requires no needles, is very easy to use, uniquely fast acting (effective blood levels in 14 minutes), safe and effective. Multi-bagger stock potential within 1 yr.

Featured Broker Partners


Advertisement